Smoking cessation drugs
Pro Research Analysisby 
Searched over 200M research papers
Smoking Cessation Drugs: Current and Emerging Pharmacotherapies
Introduction to Smoking Cessation Pharmacotherapies
Smoking cessation is a critical public health goal due to the significant health risks associated with tobacco use. Various pharmacotherapies have been developed to aid individuals in quitting smoking, with varying degrees of success and side effects. This article synthesizes the current and emerging pharmacotherapies for smoking cessation, highlighting their efficacy, safety, and potential for long-term abstinence.
First-Line Smoking Cessation Treatments: Nicotine Replacement Therapy, Bupropion, and Varenicline
Nicotine Replacement Therapy (NRT)
Nicotine Replacement Therapy (NRT) has been a cornerstone of smoking cessation treatment since its introduction in 1978. NRT is available in several forms, including patches, gum, nasal spray, inhalers, and lozenges. Studies have shown that NRT can significantly increase the chances of quitting smoking compared to placebo, with an odds ratio (OR) of 1.60 18. However, the effectiveness of NRT can vary depending on the formulation used.
Bupropion
Bupropion, an atypical antidepressant, is another first-line treatment for smoking cessation. High-certainty evidence indicates that bupropion increases long-term smoking cessation rates (RR 1.64) 27. However, it is associated with an increased risk of adverse events, including psychiatric symptoms and trial dropouts due to drug-related side effects 27. Despite these risks, bupropion remains a valuable option, particularly for individuals who may benefit from its antidepressant properties.
Varenicline
Varenicline, a partial agonist of the alpha(4)beta(2) nicotinic acetylcholine receptor, has been shown to offer significant improvements in abstinence rates over bupropion and NRT. Varenicline has an OR of 2.88 for quitting smoking compared to placebo, making it one of the most effective first-line treatments available 8. However, its safety profile requires careful monitoring, especially in patients with psychiatric comorbidities 9.
Second-Line Treatments: Nortriptyline and Clonidine
Nortriptyline
Nortriptyline, a tricyclic antidepressant, is used as a second-line treatment for smoking cessation. It has been shown to significantly increase long-term cessation rates (RR 2.03) compared to placebo 27. However, due to its potential for serious side effects, it is generally reserved for cases where first-line treatments have failed or are not tolerated 5.
Clonidine
Clonidine, an antihypertensive drug, is another second-line option. It has been found to increase the chances of quitting smoking (RR 1.63) but is associated with a dose-dependent rise in adverse events, making it less favorable compared to other treatments 8.
Emerging and Novel Therapies
Cytisine
Cytisine, a nicotine receptor partial agonist similar to varenicline, has shown promising results in increasing smoking cessation rates without significant adverse events 18. It is currently licensed in some countries and may offer an affordable alternative to other pharmacotherapies.
Acetylcholinesterase Inhibitors and N-Acetylcysteine
Novel therapies such as acetylcholinesterase inhibitors and N-acetylcysteine are being investigated for their potential to aid smoking cessation. These agents have shown promising results in preliminary studies, but more high-quality randomized controlled trials are needed to confirm their efficacy and safety 1.
Antidepressants and Anxiolytics
Antidepressants
Antidepressants, particularly bupropion and nortriptyline, have been shown to aid smoking cessation. However, other antidepressants such as SSRIs and MAOIs have not demonstrated significant benefits in helping individuals quit smoking 47. The effectiveness of these drugs may be related to their ability to alleviate depressive symptoms associated with nicotine withdrawal 24.
Anxiolytics
There is little evidence to support the use of anxiolytics for smoking cessation. Trials of drugs such as diazepam, buspirone, and beta-blockers have not shown significant effectiveness in helping smokers quit 4.
Conclusion
While first-line treatments like NRT, bupropion, and varenicline remain the most effective options for smoking cessation, second-line treatments and emerging therapies offer additional avenues for individuals who struggle to quit. The development of more effective and safer smoking cessation drugs is crucial to reducing the global burden of tobacco-related diseases. Further research is needed to explore the potential of novel therapies and to optimize existing treatments for better long-term outcomes.
Sources and full results
Most relevant research papers on this topic
Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking
Combination NRT and varenicline show the greatest smoking cessation rates, while novel therapies like acetylcholinesterase inhibitors, cytisine, and N-acetylcysteine show promising results.
Systematic ReviewAntidepressants for smoking cessation.
Bupropion effectively increases long-term smoking cessation rates, with insufficient evidence to determine if it increases the risk of serious adverse events.
Meta-Analysis
Very Rigorous JournalBeyond "Safe and Effective": The urgent need for high-impact smoking cessation medications.
High-impact smoking cessation medications with behavioral support are urgently needed to effectively increase cessation and reduce population smoking prevalence.
Meta-Analysis
Rigorous JournalAnxiolytics and antidepressants for smoking cessation.
There is little evidence that anxiolytics aid smoking cessation, while some antidepressants (bupropion and nortriptyline) can, but the effects are unclear and may be class effects.
Highly CitedUpdate on pharmacologic options for smoking cessation treatment.
Nicotine replacement therapy, bupropion, varenicline, and nortriptyline are effective smoking cessation treatments, with varenicline showing the most improvement in abstinence rates.
Highly CitedCardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis
Smoking cessation therapies, such as bupropion and varenicline, do not appear to increase the risk of serious cardiovascular disease events.
Meta-AnalysisVery Rigorous JournalHighly CitedAntidepressants for smoking cessation.
Bupropion significantly increased long-term smoking cessation when used as the sole pharmacotherapy, with high quality evidence.
Very Rigorous JournalHighly CitedPharmacological interventions for smoking cessation: an overview and network meta-analysis.
Nicotine replacement therapy, bupropion, and varenicline effectively help smokers achieve long-term abstinence, with varenicline showing the highest odds of quitting compared to placebo.
Meta-AnalysisVery Rigorous JournalHighly CitedPharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Nicotine replacement therapy, bupropion, and varenicline are effective first-line pharmacotherapies for smoking cessation, with potential second-line benefits from nortriptyline and clonidine.
Rigorous JournalHighly CitedOpioid antagonists for smoking cessation.
Naltrexone's effectiveness in promoting long-term smoking cessation remains inconclusive, with limited data from four trials suggesting both potential benefits and negative effects.
Meta-AnalysisHighly Cited